Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Richard C. Becker(Clinical Research Institute), Robert A. Harrington(Clinical Research Institute), Karen S. Pieper(Clinical Research Institute), Jinglan Pei(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gail Berman, Kenneth W. Mahaffey(Cardiovascular Institute of the South), David J. Moliterno(University of Kentucky), Diane Joseph‐McCarthy, Frans Van de Werf(KU Leuven), John Strony(University Hospitals of Cleveland), Enrico P. Veltri(United States Nuclear Regulatory Commission), Lisa K. Jennings(Saint Luke's Health System), Alan Niederman, Khaled M. Ziada(Cleveland Clinic)
Cited by 298
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k